Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Patent Landscape of BRAF Target and KRAS Target.

Recent patents on anti-cancer drug discovery - 1 Jan 2023

Zhang Hai-Long, Li Yongxia

Abstract excerpt

BACKGROUND: KRAS and BRAF targets are involved in the epidermal growth factor receptor pathway. KRAS and BRAF targets are the most frequent driver mutations in cancer. OBJECTIVE: The objective of the study was to present the recent developments in the KRAS target and the BRAF target. METHODS: KRAS target and BRAF target were analyzed by US patent analysis. All US granted patent documents from January 2002 to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Colorectal Neoplasms
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Patents as Topic

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 36475349
DOI: 10.2174/1574892818666221207091329

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Patent Landscape of BRAF Target and KRAS Target.PMID 36475349Read ↗

An updated literature on BRAF inhibitors (2018-2023).Semantic proximity Read ↗

[Expert consensus on BRAF inhibitors in the treatment of malignant solid tumors (2024 edition)].Semantic proximity Read ↗

BRAF as a therapeutic target: a patent review (2006 - 2012).Semantic proximity Read ↗

Inhibitors of the GTPase KRASG12C in cancer: a patent review (2019-2021).Semantic proximity Read ↗

KRAS Binders Hidden in NatureSemantic proximity Read ↗

KRAS-Targeting Agents in Cancer: A Bibliometric Analysis of Global Research Trends and Emerging Hotspots from 2006 to 2026Semantic proximity Read ↗

Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022Semantic proximity Read ↗

Discovery of 6-[(3 S ,4 S )-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 InhibitorSemantic proximity Read ↗

Identification of type II inhibitors targeting BRAF using privileged pharmacophores.Semantic proximity Read ↗

Targeted design, synthesis, molecular simulation, ADME-T and in-vitro anticancer assessment of phenyl-substituted-thioxo-tetrahydro-pyrimidin-benzenesulfonamide derivatives as potential BRAFV600E/WT inhibitors.Semantic proximity Read ↗

Novel inhibitors of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) based on a 2,6-disubstituted pyrazine scaffold.Semantic proximity Read ↗

Global trends and emerging insights in BRAF and MEK inhibitor resistance in melanoma: a bibliometric analysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.